7 are currently without
evidence of disease.

No non-hematologic Grade 4 adverse events were reported. Grade 4 lymphopenia, neutropenia
and thrombocytopenia were observed in 1, 2 and 2 patients, respectively. Grade 1-3 anemia,
nausea/vomiting and hypocalcemia were observed in 18, 1, and 3 patients, respectively.
“Myelosuppression, particularly neutropenia, is a substantial clinical problem in patients with
relapsed NHL,” said Dr. Scott E. Smith, MD, PhD, Assistant Professor of Medicine at Loyola,
who was the principal investigator of this trial. “Based on these favorable results, we have
organized a followup trial of GaRD used in combination with another standard regimen that we
expect to initiate in a Chicago-based clinical collaboration.”

About Ganite
Ganite was originally developed by the U.S. National Cancer Institute as a cancer chemotherapy
drug. A separate series of studies showed that the drug markedly reduced the loss of calcium
from bone - an observation that suggested the drug may be useful in hypercalcemia, as well as
other conditions associated with loss of bone mass. Ganite is approved in the U.S. for treatment
of symptomatic patients with cancer related hypercalcemia that is resistant to hydration.

Important Safety Information about Ganite® (gallium nitrate injection)
Ganite is contraindicated in patients with severe renal impairment (serum creatinine > 2.5
mg/dL). While Ganite was generally well tolerated by patients who received the drug in clinical
trials, concurrent use of Ganite with other potentially nephrotoxic drugs like aminoglycosides
and amphotericin B may increase the risk for developing severe renal insufficiency in patients
with cancer-relapsed hypercalcemia. If use of a potentially nephrotoxic drug is indicated during
Ganite therapy, Ganite should be disconti
'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery